Sou Hu Cai Jing·2025-12-23 12:31Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong performance in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit excluding non-recurring items was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2]. - The net profit for Q3 2025 was 77.06 million yuan, showing a staggering increase of 531.12% year-on-year [2]. - The net profit excluding non-recurring items for Q3 was 74.52 million yuan, up 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of December 23, 2025, the stock closed at 23.8 yuan, down 0.83%, with a turnover rate of 0.33% and a trading volume of 9,634 lots, amounting to a total transaction value of 22.9961 million yuan [1]. - On December 23, the net outflow of main funds was 1.0911 million yuan, accounting for 4.74% of the total transaction value, while retail investors saw a net inflow of 1.7341 million yuan, representing 7.54% of the total transaction value [1]. Analyst Ratings - In the past 90 days, 9 institutions have provided ratings for the stock, with 8 recommending a buy and 1 recommending an increase in holdings [2]. - The average target price set by institutions over the past 90 days is 3.18 billion yuan [2].